{
  "docId": "019de070-3f4a-73d8-b295-3b15c76ba522",
  "docSlug": "bc1fcb576f82bf5c3541f439604f314c",
  "documentTitle": "Kymera | IPO Presentation Deck | 49 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 49,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a color-coded system (blue for oncology, orange for inflammation/immunology) to distinguish therapeutic focus.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3f4a-73d8-b295-3b15c76ba522/17",
  "deckHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522",
  "deckJsonHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522.json",
  "deckAnchorHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Pipeline development timeline for IRAK4, IRAKIMiD, and STAT3 programs.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57a1e91d-c6d8-4126-a55e-810d5d539cfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.62
      },
      "kind": "legend",
      "text": "Oncology (blue) and Inflammation/Immunology (orange)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f1e0530-4d86-4577-aeb9-6733c7147248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Leveraging the capabilities of our Pegasus platform, we are also advancing: Multiple wholly-owned degrader programs in immunology-inflammation and genetically defined oncology indications; Multiple programs across several disease indications with our partners: Vertex and Sanofi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aa2e18e-c9b3-42fa-bad1-6ea99d37ce25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.05
      },
      "kind": "title",
      "text": "Robust Pipeline of Targeted Protein Degraders for Un-drugged Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e1d65d2-1681-4e61-979e-1c66a54e8c1a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "cd77ea6c-5656-43f5-b0ef-a8bc58935d27",
      "evidence": "The pipeline is visualized as a timeline of development stages for specific programs.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}